- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03462498
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS (STOPDAPT-2 ACS)
April 1, 2023 updated by: Takeshi Morimoto, Kyoto University, Graduate School of Medicine
Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The drug-eluting stents (DESs) are currently used in the majority of percutaneous coronary intervention (PCI) procedures.
On the other hand, the problems of the first-generation DES (late adverse events, such as very late stent thrombosis) have been pointed out.
Dual antiplatelet therapy (DAPT) has become a standard regimen after DES implantation and for fear of very late stent thrombosis, DAPT is frequently performed for 1 year or longer in clinical practice.
Especially guidelines recommend 1-year DAPT for patients with acute coronary syndrome (ACS), though its rational is based on the study more than 15 years old.
However, serious hemorrhagic complications associated with prolonged DAPT duration can bring disadvantages to patients, and it is extremely important to clarify an optimal DAPT duration after DES procedure.
Currently, 1-month DAPT regimen after bare metal stent (BMS) implantation is commonly used in clinical practice, producing no major problems.
Based on a meta-analysis of recent clinical studies, it has also been reported that the use of Cobalt-Chromium Everolimus-Eluting Stent (CoCr-EES) reduces the risk of early stent thrombosis by half compared to the use of BMS.
There is no necessity to extend antiplatelet therapy after CoCr-EES implantation longer than after BMS implantation, and it is considered possible to use the same 1-month DAPT duration as after BMS implantation.
The investigators already planned and started a multicenter, randomized, open-label, controlled study, in which the subjects who have undergone CoCr-EES procedure will be divided into the 1-month DAPT and clopidogrel monotherapy group and the 12-month DAPT and aspirin monotherapy group (STOPDAPT-2; NCT02619760), where primary endpoint is the incidence of composite events including cardiovascular death, myocardial infarction, stent thrombosis, stroke, and bleeding defined by TIMI major or minor bleeding.
In STOPDAPT-2, the non-inferiority about primary endpoint of 1-month DAPT group will be evaluated at 12 months after index procedure and secondarily, the superiority about primary endpoint of 1-month DAPT group will be evaluated at 5 years after index procedure.
The proportion of patients with ACS is about 30-40% in STOPDAPT-2 and the power is insufficient to evaluate the safety and efficacy of 1-month DAPT regimen specifically for patients with ACS.
Therefore the investigators planned the current study to enroll patients of ACS with the same protocol as STOPDAPT-2.
Study Type
Interventional
Enrollment (Actual)
3008
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kyoto, Japan, 606-8507
- Kyoto University Graduate School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients received percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent under the setting of acute coronary syndrome
- Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and P2Y12 receptor antagonist
Exclusion Criteria:
- Patients requiring oral anticoagulants
- Patients with medical history of intracranial hemorrhage
- Patients who have experienced serious complications (myocardial infarction, stroke, and major bleeding) during hospital stay after percutaneous coronary intervention
- Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents implanted at the time of enrollment
- Patients confirmed to have no tolerability to clopidogrel before enrollment
- Patients requiring continuous administration of antiplatelet drugs other than aspirin and P2Y12 receptor antagonists at the time of enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1-month DAPT
1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
|
1-month DAPT followed by 59-month monotherapy
|
Active Comparator: 12-month DAPT
1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
|
12-month DAPT followed by 48-month monotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group
Time Frame: 12 months
|
12 months
|
Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group
Time Frame: 60 months
|
60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular death
Time Frame: 12 months
|
12 months
|
|
Stroke
Time Frame: 12 months
|
12 months
|
|
Clinically-driven target lesion revascularization
Time Frame: 60 months
|
60 months
|
|
Target vessel revascularization
Time Frame: 12 months
|
12 months
|
|
Myocardial infarction
Time Frame: 12 months
|
12 months
|
|
Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke
Time Frame: 12 months
|
12 months
|
|
Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke
Time Frame: 60 months
|
60 months
|
|
Bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group
Time Frame: 12 months
|
12 months
|
|
Bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group
Time Frame: 60 months
|
60 months
|
|
Upper gastrointestinal endoscopic examination or treatment
Time Frame: 60 months
|
60 months
|
|
Composite event of all-cause death/myocardial infarction
Time Frame: 12 months
|
12 months
|
|
Composite event of all-cause death/myocardial infarction
Time Frame: 60 months
|
60 months
|
|
All-cause death
Time Frame: 12 months
|
12 months
|
|
All-cause death
Time Frame: 60 months
|
60 months
|
|
Composite event of cardiovascular death/myocardial infarction
Time Frame: 12 months
|
12 months
|
|
Composite event of cardiovascular death/myocardial infarction
Time Frame: 60 months
|
60 months
|
|
Cardiovascular death
Time Frame: 60 months
|
60 months
|
|
Myocardial infarction
Time Frame: 60 months
|
60 months
|
|
Stroke
Time Frame: 60 months
|
60 months
|
|
Definite stent thrombosis
Time Frame: 12 months
|
Academic Research Consortium definition
|
12 months
|
Definite stent thrombosis
Time Frame: 60 months
|
Academic Research Consortium definition
|
60 months
|
Target lesion failure
Time Frame: 12 months
|
12 months
|
|
Target lesion failure
Time Frame: 60 months
|
60 months
|
|
Target vessel failure
Time Frame: 12 months
|
12 months
|
|
Target vessel failure
Time Frame: 60 months
|
60 months
|
|
Major adverse cardiac event
Time Frame: 12 months
|
Composite of cardiac death, myocardial infarction, and clinically-driven TLR
|
12 months
|
Major adverse cardiac event
Time Frame: 60 months
|
Composite of cardiac death, myocardial infarction, and clinically-driven TLR
|
60 months
|
Target lesion revascularization
Time Frame: 12 months
|
12 months
|
|
Target lesion revascularization
Time Frame: 60 months
|
60 months
|
|
Clinically-driven target lesion revascularization
Time Frame: 12 months
|
12 months
|
|
Non target lesion revascularization
Time Frame: 12 months
|
12 months
|
|
Non target lesion revascularization
Time Frame: 60 months
|
60 months
|
|
Coronary artery bypass graft
Time Frame: 12 months
|
12 months
|
|
Coronary artery bypass graft
Time Frame: 60 months
|
60 months
|
|
Target vessel revascularization
Time Frame: 60 months
|
60 months
|
|
Any coronary revascularization
Time Frame: 12 months
|
12 months
|
|
Any coronary revascularization
Time Frame: 60 months
|
60 months
|
|
Bleeding complications
Time Frame: 12 months
|
12 months
|
|
Bleeding complications
Time Frame: 60 months
|
60 months
|
|
Gastrointestinal bleeding
Time Frame: 12 months
|
12 months
|
|
Gastrointestinal bleeding
Time Frame: 60 months
|
60 months
|
|
Gastrointestinal complaints requiring upper gastrointestinal endoscopy
Time Frame: 12 months
|
12 months
|
|
Gastrointestinal complaints requiring upper gastrointestinal endoscopy
Time Frame: 60 months
|
60 months
|
|
Newly diagnosed cancer
Time Frame: 60 months
|
The endpoint is a newly diagnosed malignancy during the follow-up period that has not been previously diagnosed before enrollment.
This does not include recurrent tumor after remission, includes early-stage cancer eligible for endoscopic treatment, and includes the tumors which are not diagnosed by tissue biopsy but are judged to be clinically malignant on imaging.
|
60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Takeshi Kimura, MD, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Obayashi Y, Watanabe H, Morimoto T, Yamamoto K, Natsuaki M, Domei T, Yamaji K, Suwa S, Isawa T, Watanabe H, Yoshida R, Sakamoto H, Akao M, Hata Y, Morishima I, Tokuyama H, Yagi M, Suzuki H, Wakabayashi K, Suematsu N, Inada T, Tamura T, Okayama H, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 and STOPDAPT-2 ACS Investigators. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. Circ Cardiovasc Interv. 2022 Aug;15(8):e012004. doi: 10.1161/CIRCINTERVENTIONS.122.012004. Epub 2022 Aug 1.
- Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S, Watanabe H, Ohya M, Tokuyama H, Tada T, Sakamoto H, Mori H, Suzuki H, Nishikura T, Wakabayashi K, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 ACS Investigators. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022 Apr 1;7(4):407-417. doi: 10.1001/jamacardio.2021.5244.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 2, 2018
Primary Completion (Actual)
December 31, 2021
Study Completion (Anticipated)
March 31, 2026
Study Registration Dates
First Submitted
March 6, 2018
First Submitted That Met QC Criteria
March 6, 2018
First Posted (Actual)
March 12, 2018
Study Record Updates
Last Update Posted (Actual)
April 4, 2023
Last Update Submitted That Met QC Criteria
April 1, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C1348
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on 1-months DAPT
-
Yonsei UniversityUnknownCoronary Artery DiseaseKorea, Republic of
-
China National Center for Cardiovascular DiseasesNot yet recruitingCoronary Artery Disease | Dual Antiplatelet Therapy | Elevated Lipoprotein(a) Level | Drug-Eluting StentChina
-
Shanghai MicroPort Medical (Group) Co., Ltd.RecruitingCoronary Disease | Percutaneous Coronary Intervention | Dual Antiplatelet Therapy | Drug Eluting StentChina
-
Kiyuk ChangSeoul St. Mary's Hospital; Korea University Guro Hospital; St Vincent's Hospital and other collaboratorsRecruitingCoronary Artery DiseaseKorea, Republic of
-
Kaiser Franz Josef HospitalWithdrawnPlatelet Dysfunction Due to Drugs | Coronary ArteriosclerosesAustria
-
Kyoto University, Graduate School of MedicineActive, not recruitingCoronary Artery DiseaseJapan
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Second Hospital of Jilin UniversitySiping Central Hospital; Beihua University; Meihekou Central Hospital; Yanbian... and other collaboratorsUnknown
-
Maasstad HospitalMedtronicCompletedMyocardial Infarction | Cardiovascular DiseaseNorway, Netherlands, Poland, Switzerland
-
Seoul National University HospitalUnknownCoronary Artery Disease | Percutaneous Coronary Intervention | Dual Antiplatelet TherapyKorea, Republic of